ImmuPharma (LON:IMM) Shares Up 30.1% - Here's What Happened

Key Points

• ImmuPharma's shares surged by 30.1% during a trading session, reaching as high as GBX 12.50 ($0.17) after previously closing at GBX 8.79 ($0.12).
• The company has a market capitalization of £56.47 million and reported a significant increase in trading volume, with 18 million shares changing hands, marking a 110% rise from average session volumes.
• ImmuPharma specializes in peptide-based therapeutics, with its lead program, Lupuzor™, targeting autoimmune diseases and demonstrating potential therapeutic activity for various conditions.

ImmuPharma plc (LON:IMM - Get Free Report) traded up 30.1% during trading on Tuesday . The company traded as high as GBX 12.50 ($0.17) and last traded at GBX 11.44 ($0.15). 18,123,977 shares changed hands during trading, an increase of 110% from the average session volume of 8,620,557 shares. The stock had previously closed at GBX 8.79 ($0.12).

ImmuPharma Trading Up 28.6%

The firm has a market cap of £56.47 million, a PE ratio of -1,269.66 and a beta of 1.53. The business's 50-day simple moving average is GBX 5.30 and its 200 day simple moving average is GBX 3.58.

ImmuPharma (LON:IMM - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. Analysts expect that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.